The critical care research specialty supports a national and international studies of high quality research relating to the care of critically ill patients. The research relates primarily to intensive care, high dependency and acute medical care.
Critical care research explores treatment and diagnostic options to decrease complications and improve outcomes for people who are critically ill. Common conditions associated with critical illnesses include sepsis, renal failure, acute respiratory failure, and shock.
Prevention, diagnosis and treatment of organ failure and long-term consequences of critical illness is the focus of critical care studies. Research nurses, intensive care consultants and trainees, research fellows, Allied Health Professionals and associate PIs form our multi-disciplinary workforce form an active research team. Much of our research work is done in collaboration with the University of Liverpool, Liverpool John Moores University and the Liverpool School of Tropical Medicine.
- This trial is currently closed to recruitment.
This trial will compare early APRV to standard lung-protective ventilation in patients with moderate to severe low oxygen levels, to see which works better and is more cost-effective. Patients will be randomly assigned to one of the two treatments while in critical care.
This UK trial will test if the steroid dexamethasone can help adults with severe lung inflammation (ARDS) who need ventilators in ICU.
This UK study will include 2,550 ICU patients needing procedures. It will test five different platelet levels to find the safest and most effective point to give platelet transfusions. Patients will be randomly assigned to one level, and if their platelet count falls below it, they’ll receive a transfusion.
This UK study will include about 2,000 ICU patients on ventilators with thick lung secretions. It will test whether two medicines—carbocisteine and hypertonic saline—help clear secretions and reduce time on ventilators
MOSAICC is a UK-wide study testing if giving sodium bicarbonate through a drip helps critically ill patients with metabolic acidosis and kidney injury survive better after 90 days.
The ABC Post Intensive Care Trial will test if giving blood transfusions to anaemic patients after leaving ICU helps improve their health and energy compared to current guidelines. Patients with low haemoglobin will be randomly assigned to different transfusion plans and followed for 6 months.
This UK study will test if giving interferon gamma (IFNg) helps critically ill adults on ventilators or needing kidney/blood pressure support who are at high risk of infections. Patients will get either one of three IFNg doses or a placebo via injections over a week.
REMAP-CAP is a global clinical trial started by ICU experts to quickly find the best treatments for patients with severe pneumonia, including COVID-19. It runs in many hospitals across multiple countries and can enroll patients fast, often in just 5 minutes by their own doctors.
This study will compare a shorter 5-day course of antibiotics to the usual longer course (around 9 days) in critically ill sepsis patients.
The ABBRUPT trial is a multi-centre study comparing two common treatments for new onset Atrial Fibrillation in intensive care patients to see which works better.
This pilot study will test how easy and useful the Cognishine platform is for hospital staff delivering therapy to patients with rehabilitation needs at Liverpool University Hospital NHS Trust.
UK-wide clinical trial across multiple hospitals to find out if targeting an early blood pressure level (MAP > 65) is better and more cost-effective for adults with septic shock compared to usual care.
Trial S-D21-C300 is a multi-centre, randomised, double-blind, placebo-controlled study in 100 ICU patients with severe community-acquired pneumonia (CAP), including COVID-19.
VITDALIZE is an international trial enrolling 2,400 patients worldwide, including 600 in the UK, to test if high-dose vitamin D improves outcomes in critically ill patients who are severely vitamin D deficient.
The aim is to see if giving Simvastatin to donors reduces inflammation and improves organ function after transplant.
